Novartis files for Japanese approval of COPD combo QVA149
This article was originally published in Scrip
Hot on the heels of the recent marketing authorization application in Europe, Novartis has filed for the Japanese approval of the combination therapy QVA149 as a once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD).
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.